A Simple Aptamer-Based Nanoconjugate Assay for Diagnosis of Chronic Myeloid Leukemia.

Chronic myeloid leukemia (CML) as a bone marrow stem cell clonal disease appears from the proliferation of granulocyte cells at all stages of maturation. If the disease diagnosis is not early, patients enter the blastic phase, which decreases their survival rate to 3-6 months. It implies the significance of the early diagnosis of CML. In this study, we introduce a simple array for diagnosis of the K562 cells as the human immortalized myeloid leukemia cell line. The developed aptamer-based biosensor (aptasensor) includes the T2-KK1B10 aptamer strands attached to the surface of mesoporous silica nanoparticles (MSNPs) with the cavities accumulated from rhodamine B and coated by both Ca2+ ions and ATP aptamer. The aptamer-based nanoconjugate can enter the K562 cells through the complexation of the T2-KK1B10 aptamer with the cells. The ATP in the cells and low level of intracellular Ca2+ ion release both the aptamer and ion from the surface of the MSNPs. The liberated rhodamine B results in an increased fluorescence intensity. Fluorescence microscope imaging and flow cytometry histogram display a strong fluorescence emission for the K562 cells (CML cells) exposed to the nanoconjugate in comparison with that for MCF-7 cells. The aptasensor possesses good performance in the blood samples with the advantages of high sensitivity, rapidness, and cost-effectiveness, making it an appropriate tool for the diagnosis of CML disease.

Diagnostic accuracy of two-dimensional coronary angiographic-derived fractional flow reserve-Preliminary results.

AIM: Noninvasive fractional flow reserve (NiFFR) is an emerging method for evaluating the functional significance of a coronary lesion during diagnostic coronary angiography (CAG). The method relies on the computational flow dynamics and the three-dimensional (3D) reconstruction of the vessel extracted from CAG. In the present study, we sought to evaluate the diagnostic performance and applicability of 2D-based NiFFR. METHODS: In this prospective observational study, we evaluated 2D-based NiFFR in 279 candidates for invasive CAG and invasive fractional flow reserve (FFR). NiFFR was calculated via two methods: variable NiFFR, in which the contrast transport time was extracted from the angiographic view, and fixed NiFFR, in which a prespecified frame count was applied. RESULTS: The final analysis was performed on 245 patients (250 lesions). Variable NiFFR had an area under the receiver operating characteristic curve of 81.5%, an accuracy of 80.0%, a sensitivity of 82.2%, a specificity of 82.2%, a negative predictive value of 91.4%, and a positive predictive value of 63.6%. The mean difference between FFR and NiFFR was -0.0244 ±.0616 (p ≤.0001). A pressure wire-free hybrid strategy was possible in 68.8% of our population with variable NiFFR. CONCLUSIONS: Our 2D-based NiFFR yielded results comparable to those derived from 3D-based software. Our findings should; however, be confirmed in larger trials.